Enovis Share Price (NYSE: ENOV)

$30.91

▲

0.32

(1.05%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Enovis Stock chart to analyse performance

Enovis stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$30.53
Today's High:$30.91
$30.91
1.23%
Downside
Day's Volatility :1.23%
Upside
0.0%
52 Weeks Low:$25.47
52 Weeks High:$49.83
$30.91
17.62%
Downside
52 Weeks Volatility :48.9%
Upside
37.97%

Enovis Stock Returns

Period	Enovis Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	4.23%	3.6%	0.0%
6 Months	-18.37%	-7.7%	0.0%
1 Year	-30.66%	-12.6%	0.0%
3 Years	-37.68%	9.5%	-4.7%

Enovis Corp Key Stats

Check Enovis key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$30.59
Open	$30.57
Today's High	$30.91
Today's Low	$30.53
Market Capitalization	$1.7B
Today's Volume	$934.3K
52 Week High	$49.83
52 Week Low	$25.465
Revenue TTM	$2.2B
EBITDA	$362.8M
Earnings Per Share (EPS)	$-14.95
Profit Margin	-37.8%
Quarterly Earnings Growth YOY	1.53%
Return On Equity TTM	-28.25%

Stock Returns calculator for Enovis Stock including INR - Dollar returns

The Enovis stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Enovis investment value today

Current value as on today

₹74,636

Returns

₹25,364

(-25.36%)

Returns from Enovis Stock

₹30,648 (-30.65%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Enovis Stock

300%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Enovis Stock from India on INDmoney has increased by 300% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Enovis Corp

Name
Holdings %
Name
Holdings %
BlackRock Inc
12.53%
Vanguard Group Inc
11.19%
American Century Companies Inc
8.29%
Dimensional Fund Advisors, Inc.
5.11%
Davenport & Company LLC
4.97%
Dorsey Asset Management, LLC
4.47%

Analyst Recommendation on Enovis Stock

Rating

Trend

Buy

88%Buy

11%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Enovis(by analysts ranked 0 to 5 stars)

Enovis Share Price Target

What analysts predicted

Upside of 68.88%

Target:

$52.20

Current:

$30.91

Enovis share price target is $52.20, a slight Upside of 68.88% compared to current price of $30.91 as per analysts' prediction.

Enovis Stock Insights

Price Movement
In the last 1 month, ENOV stock has moved up by 14.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 558.83M → 564.54M (in $), with an average increase of 1.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -703.33M → -36.64M (in $), with an average increase of 604.7% per quarter
ENOV vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 62.7%
ENOV vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 163.5% return, outperforming this stock by 203.3%
Price to Sales
ForENOV every $1 of sales, investors are willing to pay $0.8, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Enovis Corp Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$3.3B	↓ 9.25%
Net Income	$-517.1M	↓ 468.87%
Net Profit Margin	-15.54%	↓ 19.36%

	FY20	Y/Y Change
Revenue	$1.1B	↓ 66.32%
Net Income	$42.6M	↓ 108.24%
Net Profit Margin	3.8%	↑ 19.34%

	FY21	Y/Y Change
Revenue	$1.4B	↑ 27.26%
Net Income	$71.7M	↑ 68.11%
Net Profit Margin	5.02%	↑ 1.22%

	FY22	Y/Y Change
Revenue	$1.6B	↑ 9.6%
Net Income	$-15.0M	↓ 120.92%
Net Profit Margin	-0.96%	↓ 5.98%

	FY23	Y/Y Change
Revenue	$1.7B	↑ 9.22%
Net Income	$-33.3M	↑ 121.86%
Net Profit Margin	-1.95%	↓ 0.99%

	FY24	Y/Y Change
Revenue	$2.1B	↑ 23.46%
Net Income	$-825.5M	↑ 2381.87%
Net Profit Margin	-39.17%	↓ 37.22%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$516.3M	↑ 13.46%
Net Income	$-72.0M	↓ 2529.08%
Net Profit Margin	-13.95%	↓ 14.6%

	Q2 FY24	Q/Q Change
Revenue	$525.2M	↑ 1.72%
Net Income	$-18.6M	↓ 74.11%
Net Profit Margin	-3.55%	↑ 10.4%

	Q3 FY24	Q/Q Change
Revenue	$505.2M	↓ 3.8%
Net Income	$-31.5M	↑ 69.12%
Net Profit Margin	-6.24%	↓ 2.69%

	Q4 FY24	Q/Q Change
Revenue	$561.0M	↑ 11.04%
Net Income	$-703.3M	↑ 2131.33%
Net Profit Margin	-125.38%	↓ 119.14%

	Q1 FY25	Q/Q Change
Revenue	$558.8M	↓ 0.38%
Net Income	$-56.0M	↓ 92.04%
Net Profit Margin	-10.01%	↑ 115.37%

	Q2 FY25	Q/Q Change
Revenue	$564.5M	↑ 1.02%
Net Income	$-36.6M	↓ 34.52%
Net Profit Margin	-6.49%	↑ 3.52%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$1.4B	↑ 23.68%

	FY20	Y/Y Change
Profit	$1.1B	↓ 18.9%

	FY21	Y/Y Change
Profit	$657.9M	↓ 42.1%

	FY22	Y/Y Change
Profit	$869.4M	↑ 32.15%

	FY23	Y/Y Change
Profit	$990.8M	↑ 13.96%

	FY24	Y/Y Change
Profit	$1.2B	↑ 19.17%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$297.9M	↑ 12.67%

	Q2 FY24	Q/Q Change
Profit	$247.9M	↓ 16.77%

	Q3 FY24	Q/Q Change
Profit	$327.4M	↑ 32.04%

	Q4 FY24	Q/Q Change
Profit	$307.5M	↓ 6.07%

	Q1 FY25	Q/Q Change
Profit	$332.2M	↑ 8.04%

	Q2 FY25	Q/Q Change
Profit	$334.7M	↑ 0.74%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$130.9M	↓ 42.15%
Investing Cash Flow	$-1.6B	↑ 872.74%
Financing Cash Flow	$1.4B	↓ 3004.36%

	FY20	Y/Y Change
Operating Cash Flow	$301.9M	↑ 130.58%
Investing Cash Flow	$-175.1M	↓ 89.28%
Financing Cash Flow	$-131.7M	↓ 109.61%

	FY21	Y/Y Change
Operating Cash Flow	$356.1M	↑ 17.94%
Investing Cash Flow	$-320.5M	↑ 83.05%
Financing Cash Flow	$584.9M	↓ 544.29%

	FY22	Y/Y Change
Operating Cash Flow	$-55.9M	↓ 115.69%
Investing Cash Flow	$-176.4M	↓ 44.96%
Financing Cash Flow	$-465.1M	↓ 179.52%

	FY23	Y/Y Change
Operating Cash Flow	$135.0M	↓ 341.65%
Investing Cash Flow	$-242.5M	↑ 37.46%
Financing Cash Flow	$127.8M	↓ 127.48%

	FY24	Y/Y Change
Operating Cash Flow	$113.5M	↓ 15.92%
Investing Cash Flow	$-955.5M	↑ 294.06%
Financing Cash Flow	$846.8M	↑ 562.63%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-36.2M	↓ 152.85%
Investing Cash Flow	$-797.8M	↑ 1243.8%
Financing Cash Flow	$864.5M	↑ 30898.21%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$7.8M	↓ 121.5%
Investing Cash Flow	$-41.3M	↓ 94.82%
Financing Cash Flow	$2.5M	↓ 99.71%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$53.6M	↑ 589.01%
Investing Cash Flow	$-58.4M	↑ 41.37%
Financing Cash Flow	$-148.0K	↓ 105.9%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$88.3M	↑ 64.93%
Investing Cash Flow	$-57.9M	↓ 0.92%
Financing Cash Flow	$-20.1M	↑ 13467.57%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-1.6M	↓ 101.81%
Investing Cash Flow	$-60.5M	↑ 4.55%
Financing Cash Flow	$51.2M	↓ 354.94%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$47.8M	↓ 3093.05%
Investing Cash Flow	$-49.8M	↓ 17.71%
Financing Cash Flow	$6.2M	↓ 87.83%

Enovis Technicals Summary

Sell

Neutral

Buy

Enovis is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Enovis Corp Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Enovis Corp	20.07%	-18.37%	-30.66%	-37.68%	-7.58%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	5.15%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Enovis Corp	15.87	NA	1.9	3.13	-0.28	0.01	NA	45.11
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Enovis Corp	Buy	$1.7B	-7.58%	15.87	-37.8%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Enovis Corp

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Organization	Enovis
Employees	7367
CEO	Mr. Damien McDonald
Industry	Capital Goods

Key Management of Enovis Corp

Name	Title
Mr. Phillip Benjamin Berry	Senior VP & CFO
Mr. Bradley J. Tandy J.D.	Senior VP & Chief Legal Officer
Ms. Patricia A. Lang	Senior VP & Chief Human Resources Officer
Mr. Daniel A. Pryor	Executive Vice President of Strategy & Business Development
Mr. Damien McDonald	CEO & Director
Mr. John Kleckner	VP, Controller & Chief Accounting Officer
Mr. Kyle William Rose	Vice President of Investor Relations
Katie Sweet	Vice President of Corporate Communication
Mr. Kenneth Daniel Konopa	Senior Vice President of Enovis Growth Excellence
Mr. Tim Czartoski	President of U.S. Surgical and Global Product & Enabling Technologies

Important FAQs about investing in ENOV Stock from India :

What is Enovis share price today?

Enovis share price today is $30.91 as on August 30, 2025 at 1:29 am IST at the close of the market. Enovis share today touched a day high of $30.91 and a low of $30.53.

What is the 52 week high and 52 week low for Enovis share?

Enovis share touched a 52 week high of $49.83 and a 52 week low of $25.47. Enovis stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $30.91, lower by 37.97% versus the 52 week high.

How to invest in Enovis Stock (ENOV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Enovis on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Enovis Shares that will get you 0.0485 shares as per Enovis share price of $30.91 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Enovis Stock (ENOV) from India?

Indian investors can start investing in Enovis (ENOV) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Enovis stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Enovis share’s latest price of $30.91 as on August 30, 2025 at 1:29 am IST, you will get 0.3235 shares of Enovis. Learn more about fractional shares .

What are the returns that Enovis has given to Indian investors in the last 5 years?

Enovis stock has given -7.58% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?